Literature DB >> 23649183

Immune activation in irritable bowel syndrome: can neuroimmune interactions explain symptoms?

Patrick A Hughes1, Heddy Zola, Irmeli A Penttila, L Ashley Blackshaw, Jane M Andrews, Doreen Krumbiegel.   

Abstract

Irritable bowel syndrome (IBS) is a functional disorder of the gastrointestinal (GI) tract characterized by pain or discomfort from the lower abdominal region, which is associated with altered bowel habit. Despite its prevalence, there is currently a lack of effective treatment options for patients. IBS has long been considered as a neurological condition resulting from alterations in the brain gut axis, but immunological alterations are increasingly reported in IBS patients, consistent with the hypothesis that there is a chronic, but low-grade, immune activation. Mediators released by immune cells act to either dampen or amplify the activity of GI nerves. Release of a number of these mediators correlates with symptoms of IBS, highlighting the importance of interactions between the immune and the nervous systems. Investigation of the role of microbiota in these interactions is in its early stages, but may provide many answers regarding the mechanisms underlying activation of the immune system in IBS. Identifying what the key changes in the GI immune system are in IBS and how these changes modulate viscerosensory nervous function is essential for the development of novel therapies for the underlying disorder.

Entities:  

Mesh:

Year:  2013        PMID: 23649183     DOI: 10.1038/ajg.2013.120

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  43 in total

Review 1.  Gut microbiota role in irritable bowel syndrome: New therapeutic strategies.

Authors:  Eleonora Distrutti; Lorenzo Monaldi; Patrizia Ricci; Stefano Fiorucci
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

2.  Global Cytokine Profiles and Association With Clinical Characteristics in Patients With Irritable Bowel Syndrome.

Authors:  Sean M P Bennet; Annikka Polster; Hans Törnblom; Stefan Isaksson; Sandrine Capronnier; Aurore Tessier; Boris Le Nevé; Magnus Simrén; Lena Öhman
Journal:  Am J Gastroenterol       Date:  2016-06-07       Impact factor: 10.864

Review 3.  The nervous and the immune systems: conspicuous physiological analogies.

Authors:  Julio Sotelo
Journal:  J Comp Physiol A Neuroethol Sens Neural Behav Physiol       Date:  2014-11-15       Impact factor: 1.836

4.  Incidence and predictive factors of irritable bowel syndrome after acute diverticulitis in Korea.

Authors:  Sungmo Jung; Hyuk Lee; Hyunsoo Chung; Jun Chul Park; Sung Kwan Shin; Sang Kil Lee; Yong Chan Lee
Journal:  Int J Colorectal Dis       Date:  2014-09-26       Impact factor: 2.571

Review 5.  Brain-gut microbiome interactions and functional bowel disorders.

Authors:  Emeran A Mayer; Tor Savidge; Robert J Shulman
Journal:  Gastroenterology       Date:  2014-02-28       Impact factor: 22.682

Review 6.  Gut/brain axis and the microbiota.

Authors:  Emeran A Mayer; Kirsten Tillisch; Arpana Gupta
Journal:  J Clin Invest       Date:  2015-02-17       Impact factor: 14.808

Review 7.  Irritable bowel syndrome: a gut microbiota-related disorder?

Authors:  Yogesh Bhattarai; David A Muniz Pedrogo; Purna C Kashyap
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-11-23       Impact factor: 4.052

8.  New and Emerging Treatment Options for Irritable Bowel Syndrome.

Authors:  Brian E Lacy; William D Chey; Anthony J Lembo
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-04

Review 9.  Effects of Self-Management Interventions in Patients With Irritable Bowel Syndrome: Systematic Review.

Authors:  Xiaomei Cong; Mallory Perry; Katherine M Bernier; Erin E Young; Angela Starkweather
Journal:  West J Nurs Res       Date:  2017-08-30       Impact factor: 1.967

10.  Adrenal and Thyroid Supplementation Outperforms Nutritional Supplementation and Medications for Autoimmune Thyroiditis.

Authors:  Christopher Wellwood; Sean Rardin
Journal:  Integr Med (Encinitas)       Date:  2014-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.